Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of D-0120 in Primary Hyperuricemia
NCT05504083Phase 2Completed
- Sponsor
- InventisBio
- Start
- Sep 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of darbinurad in Primary Hyperuricemia, sponsored by InventisBio. Started Sep 2022; status: completed.
02
Drugs
darbinurad
03
Conditions
Primary Hyperuricemia
Beyond the preview
Go deeper on NCT05504083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504083.